BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bashir Q, Qazilbash MH. Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work. Curr Hematol Malig Rep 2017;12:126-35. [PMID: 28285435 DOI: 10.1007/s11899-017-0374-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Susanibar Adaniya SP, Cohen AD, Garfall AL. Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications. Am J Hematol 2019;94:S28-33. [PMID: 30730071 DOI: 10.1002/ajh.25428] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
2 Atrash S, Ali SA, Usmani SZ. Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2021;21:21-34. [PMID: 33046423 DOI: 10.1016/j.clml.2020.08.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Lopes R, Ferreira BV, Caetano J, Barahona F, Carneiro EA, João C. Boosting Immunity against Multiple Myeloma. Cancers (Basel) 2021;13:1221. [PMID: 33799565 DOI: 10.3390/cancers13061221] [Reference Citation Analysis]
4 Bryant AR, Hilden P, Giralt S, Chung DJ, Maloy M, Landau H, Landgren O, Scordo M, Shah G, Smith EL, O'Reilly RJ, Perales MA, Koehne G. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 2020;26:58-65. [PMID: 31493537 DOI: 10.1016/j.bbmt.2019.08.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Vulpis E, Stabile H, Soriani A, Fionda C, Petrucci MT, Mariggio' E, Ricciardi MR, Cippitelli M, Gismondi A, Santoni A, Zingoni A. Key Role of the CD56lowCD16low Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells. Cancers (Basel) 2018;10:E473. [PMID: 30501078 DOI: 10.3390/cancers10120473] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
6 Cohen AD. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update. American Society of Clinical Oncology Educational Book 2018. [DOI: 10.1200/edbk_200889] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
7 Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B, Pasquini MC, Hamadani M, Hari PN. Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. Biol Blood Marrow Transplant 2020;26:1288-97. [PMID: 32135202 DOI: 10.1016/j.bbmt.2020.02.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
8 Yin X, Tang L, Fan F, Jiang Q, Sun C, Hu Y. Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017. Cancer Cell Int 2018;18:62. [PMID: 29713245 DOI: 10.1186/s12935-018-0553-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
9 Munker R, Monohan G. Progress in multiple myeloma. Indian J Med Res 2019;149:693-4. [PMID: 31496521 DOI: 10.4103/ijmr.IJMR_770_19] [Reference Citation Analysis]